CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- FinancialsAltman Z-Score 4.22: safe zone
- Interpretations2 currently firing — 2
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
4.67BCNY697.02M · vs all stocks (USD)
Revenue (TTM)
1.16BCNY173.60M · vs all stocks (USD)
Profit Margin
-3.69%vs Biotechnology peers
Beta
0.6940xvs all stocks
52-Week Change
-26.59%vs all stocks
Market Capitalization
4.67BCNY697.02M · vs all stocks (USD)
Enterprise Value
4.61BCNY688.20M · vs all stocks (USD)
Forward P/E
23.13xvs Biotechnology peers
Price to Sales (TTM)
4.02xvs Biotechnology peers
Price to Book (MRQ)
3.93xvs Biotechnology peers
Enterprise to Revenue
3.96xvs Biotechnology peers
Enterprise to EBITDA
152.86xvs Biotechnology peers
Gross Margin
25.02%vs Biotechnology peers
Profit Margin
-3.69%vs Biotechnology peers
Operating Margin
0.42%vs Biotechnology peers
Return on Assets (TTM)
-0.60%vs Biotechnology peers
Return on Equity (TTM)
-3.29%vs Biotechnology peers
Revenue (TTM)
1.16BCNY173.60M · vs all stocks (USD)
Revenue per Share (TTM)
2.60CNYUpdated Sep 20, 2026Quarterly Revenue Growth
8.50%vs Biotechnology peers
Gross Profit (TTM)
311.27MCNY46.45M · vs all stocks (USD)
EBITDA (TTM)
167.83MCNY25.04M · vs all stocks (USD)
Net Income (TTM)
-42.96MCNY-6.41M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
13.21%vs Biotechnology peers
Operating Cash Flow (TTM)
165.13MCNY24.64M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
38.90MCNY5.80M · vs all stocks (USD)
5-Year Average Dividend Yield
0.47%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Minority Interest (Equity)
24.34MCNYFY2025 · Dec 31, 2025Revenue
1.13BCNYFY2025 · Dec 31, 2025Cost of Goods Sold
810.03MCNYFY2025 · Dec 31, 2025Gross Profit
324.69MCNYFY2025 · Dec 31, 2025Operating Income
39.10MCNY5.83M · vs all stocks (USD)
Pre-tax Income
16.01MCNYFY2025 · Dec 31, 2025Income Tax Expense
2.46MCNYFY2025 · Dec 31, 2025Net Income
13.55MCNYFY2025 · Dec 31, 2025EBIT
31.88MCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
167.83MCNYFY2025 · Dec 31, 2025Research & Development
59.84MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
94.98MCNYFY2025 · Dec 31, 2025Other Operating Expenses
4.20MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
9.86MCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
15.86MCNYFY2025 · Dec 31, 2025EPS (Basic)
0.0300CNYFY2025 · Dec 31, 2025EPS (Diluted)
0.0300CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
447.07MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
447.07MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
13.55MCNYFY2025 · Dec 31, 2025Minority Interests (P&L)
-140.89KCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
-12.12MCNYFY2025 · Dec 31, 2025Free Cash Flow
-74.41MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
405.48MCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
13.55MCNYFY2025 · Dec 31, 2025Other Non-cash Items
64.68MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-89.40MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-957.65KCNYFY2025 · Dec 31, 2025Capital Expenditures
-62.29MCNYFY2025 · Dec 31, 2025Purchase of Investments
-21.65MCNYFY2025 · Dec 31, 2025Sale of Investments
60.25MCNYFY2025 · Dec 31, 2025Other Investing Activity
-46.22MCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
-69.90MCNYFY2025 · Dec 31, 2025Long-term Debt Issuance
21.00MCNYFY2025 · Dec 31, 2025Long-term Debt Payments
-47.53MCNYFY2025 · Dec 31, 2025Common Dividends Paid
-2.90MCNYFY2025 · Dec 31, 2025Other Financing Charges
-50.28MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
-79.71MCNYFY2025 · Dec 31, 2025Shares Outstanding
497.96MSharesUpdated Sep 20, 2026Float Shares
291.79MSharesUpdated Sep 20, 2026% Held by Insiders
29.98%vs all stocks
% Held by Institutions
1.44%vs all stocks
Total Cash (MRQ)
408.07MCNY60.89M · vs all stocks (USD)
Total Cash per Share (MRQ)
0.8080CNYUpdated Sep 20, 2026Total Debt (MRQ)
424.98MCNY63.42M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.3255xvs Biotechnology peers
Current Ratio (MRQ)
2.18xvs Biotechnology peers
Book Value per Share (MRQ)
2.35CNYUpdated Sep 20, 2026Total Assets
2.03BCNY303.36M · vs all stocks (USD)
Total Current Assets
765.02MCNYFY2025 · Dec 31, 2025Total Liabilities
732.59MCNYFY2025 · Dec 31, 2025Total Non-current Assets
1.27BCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
377.14MCNYFY2025 · Dec 31, 2025Total Current Liabilities
355.45MCNYFY2025 · Dec 31, 2025Cash
405.45MCNYFY2025 · Dec 31, 2025Cash Equivalents
6.38MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
411.83MCNYFY2025 · Dec 31, 2025Other Short-term Investments
45.57MCNYFY2025 · Dec 31, 2025Accounts Receivable
229.26MCNYFY2025 · Dec 31, 2025Inventory
9.47MCNYFY2025 · Dec 31, 2025Accounts Payable
50.31MCNYFY2025 · Dec 31, 2025Short-term Debt
135.22MCNYFY2025 · Dec 31, 2025Other Current Liabilities
1.02MCNYFY2025 · Dec 31, 2025Long-term Debt
333.95MCNYFY2025 · Dec 31, 2025Other Non-current Liabilities
13.57MCNYFY2025 · Dec 31, 2025Common Stock (Book)
497.96MCNYFY2025 · Dec 31, 2025Retained Earnings
-667.16MCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
1.30BCNY194.04M · vs all stocks (USD)
52-Week Low
7.22CNYUpdated Sep 20, 202652-Week High
14.23CNYUpdated Sep 20, 202652-Week Change
-26.59%vs all stocks
Beta
0.6940xvs all stocks
50-Day MA
9.67CNYUpdated Sep 20, 2026200-Day MA
9.95CNYUpdated Sep 20, 2026Avg 10-Day Volume
17.27MSharesUpdated Sep 20, 2026Avg 30-Day Volume
32.91MSharesUpdated Sep 20, 2026Diluted EPS (TTM)
-0.0800CNYUpdated Sep 20, 20262 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
Multi-Year Debt Decrease With Cash Near Total Debt And Equity
Long-term debt down in each of four years, and cash now covers most or all of what is left.
Reads
How does this company use capital?
Industry-Benchmarked Return on Capital Elevated
It earns more on its assets and its equity than its industry, and gets more sales from those assets.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Financial Health
Altman Z-Score 4.22: safe zoneNotable
Altman Z-Score: 4.22
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Companies that share the same coordination system — how they create, deliver, or capture value.
Revenio Group Oyj
Tier 1ProductionApproval-Gated PipelineRule
Zhejiang Anglikang Pharmaceuticals Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Zhejiang Wecome Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Collegium Pharmaceutical Inc.
Tier 1ProductionApproval-Gated PipelineRule
Morepen Laboratories Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Verastem Inc.
Tier 1ProductionApproval-Gated PipelineRule
Annexon, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Hunan Fangsheng Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Gen Ilac ve Saglik Urunleri A.S.
Tier 1ProductionApproval-Gated PipelineRule
Genomma Lab Internacional S.A.B. de C.V.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Companies that share active interpretations — structural patterns currently present in both stocks.
TV Tokyo Holdings Corporation
2 interpretationsMulti-Year Debt Decrease With Cash Near Total Debt And EquityIndustry-Benchmarked Return on Capital Elevated
Tactile Systems Technology Inc.
2 interpretationsMulti-Year Debt Decrease With Cash Near Total Debt And EquityIndustry-Benchmarked Return on Capital Elevated
Amlogic (Shanghai) Co., Ltd.
2 interpretationsMulti-Year Debt Decrease With Cash Near Total Debt And EquityIndustry-Benchmarked Return on Capital Elevated